人間のアポプロテインA-1遺伝子に隣接するDNAポリモルフィズム:ハイパートリグリセリデミアとの関係
Lancet (London, England)
|February 26, 1983
まとめ
人間のアポプロテイン-A-1遺伝子に近いDNAポリモルフィズムは,高トリグリセリデミア患者でより一般的です. この遺伝子変異は,高トリグリセリドレベルへの予備性を示す可能性があります.
科学分野:
- 遺伝学 遺伝学とは
- 分子生物学は分子生物学である.
- バイオケミストリー バイオケミストリー
背景:
- アポリポプロテインA-1 (ApoA-1) は,脂質代謝において重要な役割を果たしています.
- アポリポプロテインA-1遺伝子領域の遺伝的変異は,脂質プロファイルに影響を与える可能性があります.
- ハイパートリグリセリデミアは,心血管疾患の重要な危険因子です.
研究 の 目的:
- 人間のアポプロテイン-A-1遺伝子の3'-側面領域における特定のDNAポリモルフィズムと高トリグリセリデミアの関連性を調査する.
- 健康な個人および高トリグリセリデミアの患者におけるこの多形態化の頻度を決定する.
主な方法:
- DNAシーケンシングは,ポリモルフィズムを特定し,ゲノタイプ化するために使用されました.
- アレルとゲノタイプの頻度が計算され,患者と対照群の間で比較されました.
主要な成果:
- 人間のアポプロテイン-A-1遺伝子の3'-側面領域でDNAポリモルフィズムが特定されました.
- ヘテロジゴス状態の頻度は,健康な対照群で約0.05であった (n=73).
- ハイパートリグリセリデミアの被験者 (n=35) では,ポリモルフィックサイト頻度は0.34で,2人のホモジゴス個体がありました.
結論:
- ハイパートリグリセリデミア患者で観察された変異性アレルのより高い頻度は,潜在的な遺伝的関連を示唆しています.
- このポリモルフィズムは,アポプロテイン-A-1遺伝子の異常のマーカーとして機能し,ApoA-1の発現または構造に影響を与える可能性があります.
- これらの遺伝的変異は,個人をハイパートリグリセリデミアに誘発する可能性があります.
関連する概念動画
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...